-
Lancet Oncol: Ipilimumab combined with anti-PD-1 therapy significantly improved the clinical prognosis of patients with advanced melanoma resistant to PD-1
Time of Update: 2021-05-20
Two reported grade 3-5 adverse events similar proportion of patients with immuneTo sum up, in patients with melanoma who are resistant to anti-PD-(L)1 therapy, the efficacy of ipilimumab combined with anti-PD-1 therapy is significantly higher than that of ipilimumab monotherapy, which not only improves the objective remission rate, but also Both progression-free survival and overall survival were significantly prolonged .
-
Stroke: Medium and long-term outcomes of reperfusion therapy in cancer patients
Time of Update: 2021-05-20
Although the long-term prognosis of the active cancer group is worse than that of the inactive cancer group, there are still many patients with good functional prognosis, especially those with a clear cause of stroke .
In patients with active cancer, reperfusion therapy has similar adverse events and short-term outcomes to other groups.
-
JAMA Oncol: Both advanced molecular thyroid tests can reduce the need for diagnostic surgery
Time of Update: 2021-05-20
A new study compares the performance characteristics of RNA testing and DNA RNA testing to predict the risk of malignancy for approximately 20% of thyroid nodules that show uncertain fine-needle aspiration (FNA) cytology results.
-
Annual Reviews of Immunology: Zhang Zemin from Peking University reviewed the progress and application of single cell technology in the field of tumor microenvironment and immunotherapy
Time of Update: 2021-05-20
: Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor MicroenvironmentThis review system summarizes the recent research progress of single-cell transcriptome technology in the analysis of tumor microenvironment, including the new characteristics of infiltrating T cells and myeloid immune cells, as well as its application and potential in revealing tumor immunotherapy mechanisms.
-
Journal of Nuclear Medicine: US single-center study found that black prostate cancer 68Ga-PSMA-11 PET imaging is less likely to be used
Time of Update: 2021-05-20
Among patients undergoing molecular imaging examinations for prostate cancer at a single higher medical center in the United States, through clinical trials, black patients have a significantly limited chance of obtaining 68 Ga-PSMA-11 PET compared with non-Hispanic white patients , nearly four times.
-
Ther Adv Med Oncol: Hormone receptor status affects the effect of high BMI and hyperglycemia on the risk of tumor recurrence in patients with early HER2+ breast cancer
Time of Update: 2021-05-20
1177/17588359211006960">Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients .
1177/17588359211006960">Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients in this message
-
JNCCN: The efficacy of treatment with abecilil after the progression of the CDK4/6 inhibitor piperisil in breast cancer patients: multi-center clinical experience
Time of Update: 2021-05-20
The current study confirms that three CDK4/6 inhibitor drugs (pibaciclib, abeciclib, ribociclib) combined with endocrine therapy can improve the progression-free survival (PFS) of HR+/HER2-MBC.
The current study confirms that three CDK4/6 inhibitor drugs (pibaciclib, abeciclib, ribociclib) combined with endocrine therapy can improve the progression-free survival (PFS) of HR+/HER2-MBC.
-
Liver Cancer: Pembrolizumab (Pembrolizumab) second-line application in advanced liver cancer efficacy: subgroup analysis results from KEYNOTE-240 Asian population
Time of Update: 2021-05-20
Treatment-related adverse eventsIn summary, pembrolizumab is effective in the second-line treatment of advanced liver cancer in Asian population and the toxicity is tolerable.
In summary, pembrolizumab is effective in the second-line treatment of advanced liver cancer in Asian populations and the toxicity is tolerable.
-
Eur J Cancer: First-line immune checkpoint inhibitor combination therapy can significantly improve the clinical prognosis of metastatic urothelial cancer
Time of Update: 2021-05-20
ICI monotherapy does not improve the tumor prognosis of patients compared with chemotherapy alone, but the safety prognosis is relatively goodIn summary, the analysis suggests that mUC patients who are eligible for chemotherapy are better than standard chemotherapy when using ICI combination therapy as a first-line treatment plan .
-
Nature: The Nobel Prize winner recently discovered that organisms can actually squeeze to remove cancer cells, bringing new ideas for cancer treatment
Time of Update: 2021-05-20
On May 5, 2021, the Nobel Prize winner and MIT Professor Robert Horvitz team published a research paper titled: Replication stress promotes cell elimination by extrusion in the Nature journal.
-
JCO: The efficacy and safety of Lifileucel (a treatment based on tumor infiltrating lymphocytes) in metastatic melanoma
Time of Update: 2021-05-20
Lifileucel treatment is effective for metastatic melanoma, including patients who are resistant to PD1 or PDL1 inhibitors.
Lifileucel treatment is effective for metastatic melanoma, including patients who are resistant to PD1 or PDL1 inhibitors.
-
JCO: Levatinib may be used to treat advanced gastrointestinal pancreatic neuroendocrine tumors!
Time of Update: 2021-05-20
To evaluate the efficacy and safety of lenvatinib in patients with advanced GEP-NETs who have previously been treatedThis is a multi-center, single-arm, open-label Phase II clinical trial, divided into two parallel cohorts, involving 21 units in 4 European countries.
-
JCO: Pertuzumab combined with high-dose trastuzumab is expected to improve the prognosis of HER2-positive breast cancer patients with brain metastases
Time of Update: 2021-05-20
With the successive clinical application of trastuzumab and pertuzumab, the prognosis of patients with HER2-positive breast cancer has been significantly improved.
This article reports the efficacy and safety evaluation of Pertuzumab combined with high-dose trastuzumab in HER2-positive breast cancer patients with brain metastases.
-
J Immunother Cancer: Shocked!
Time of Update: 2021-05-20
1136/jitc-2021-002535" target="_blank" rel="noopener">Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis .
-
J Thorac Oncol: Phase 3 clinical trial results of niraparib as the first-line maintenance treatment for platinum-sensitive patients with extensive-stage small cell lung cancer in China
Time of Update: 2021-05-20
ZL-2306-005 is a randomized, double-blind, multicenter phase 3 study to evaluate the use of the PARP inhibitor niraparib as a platinum-sensitive extensive-stage small cell lung cancer (ES-SCLC) patient in China The effectiveness and safety of the first-line maintenance treatment.
-
J Immunother Cancer: The dynamic changes of tumor-infiltrating immune cells can predict the patient's response to neoadjuvant chemotherapy
Time of Update: 2021-05-20
com/content/9/5/e002198" target="_blank" rel="noopener">Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial Journal for ImmunoTherapy of Cancer 2021;9:e002198.
-
Br J Cancer: GNG4, a potential therapeutic target for liver metastases from gastric cancer
Time of Update: 2021-05-20
In this study, the researchers conducted transcriptomic analysis of liver metastases, primary tumors and adjacent tissues in patients with liver metastasis to gastric cancer, aiming to discover new genes that promote liver metastasis in an organ-oriented method, and for advanced gastric cancer Treatment provides a certain theoretical basis.
-
NEJM: The effect of anti-B cell maturation antigen CAR-T cell therapy bb2121 in the treatment of multiple myeloma
Time of Update: 2021-05-20
gov/31042825/" target="_blank" rel="noopener">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma .
gov/31042825/" target="_blank" rel="noopener">Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma in this message
-
Journal of Nuclear Medicine: 18F-FDG PET / CT can detect metastasis of urethral adenocarcinoma and guide changes in staging and patient management
Time of Update: 2021-05-20
18 18In summary, 18 F-FDG PET/CT has clinical practical value in UrC-ADC patients.
18 F-FDG PET/CT has clinical practical value in UrC-ADC patients.
18 18F-FDG PET/CThas clinical practical value in UrC-ADC patients.
-
Clin Cancer Res: The impact of different treatments and gene mutations on the prognosis of patients with intrahepatic cholangiocarcinoma
Time of Update: 2021-05-20
For IHC patients with positive lymph node metastasis, there is no difference in survival between surgical resection and hepatic artery infusion chemotherapy, but both are better than system chemotherapy alone.
